×

Major Shareholder Announcement

COPENHAGEN, Denmark, June 12, 2015 (GLOBE NEWSWIRE) -- Zealand Pharma ("Zealand") (Nasdaq Copenhagen: ZEAL) has today received a major shareholder notification from Legg Mason, Inc., 100 International Drive, 9th Fl., Baltimore, Maryland 21202, the United States (CVR-no. US-D01223502). Legg Mason, Inc. is the parent company of Royce & Associates LLC, manager of a list of funds and trusts.

Pursuant to Section 29 of the Danish Securities Act, cf. executive order no. 668 of 25 June 2012 on major shareholders and the Danish Companies Act section 55, cf. section 56, Zealand has been notified that Legg Mason, Inc. control voting rights on 1,198,550 shares, corresponding to 5.10% of the total voting rights in Zealand.

For further information, please contact:

Hanne Leth Hillman, Senior Vice President, Investor Relations & Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S ("Zealand") (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a proprietary pipeline of novel medicines alongside a partnered product and development portfolio.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia(r) and is in Phase III development as a single-injection combination with Lantus(r) (LixiLan), both under a global license agreement with Sanofi. US regulatory filing for Lyxumia(r) is planned for Q3 2015 and filing for LixiLan is planned for Q4 2015 in the US and Q1 2016 in Europe.

Zealand's proprietary pipeline includes danegaptide (prevention of Ischemic Reperfusion Injury) and two stable glucagon products, ZP4207 (one for treatment of severe hypoglycemia and the other for mild to moderate hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company's products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma

Source: Zealand Pharma A/S